Results 151 to 160 of about 1,519,715 (337)
Molecular Oncology, EarlyView.This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima +6 more
wiley +1 more source
Liver resection for metastatic colorectal cancer [PDF]
, 1986 From 1975 to 1985, 60 patients with isolated hepatic metastases from colorectal cancer were treated by 17 right trisegmentectomies, five left trisegmentectomies, 20 right lobectomies, seven left lobectomies, eight left lateral segmentectomies, and three ...
Esquivel, CO +3 more
core
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
Molecular Oncology, EarlyView.In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza +3 more
wiley +1 more source
Changing perspectives on liver transplantation in 1988. [PDF]
, 1988 After liver transplantation for cancer, there is a high incidence of disease recurrence within 18 to 36 months for most tumors, although there are a small number of long-term survivors.
Gordon, RD, Starzl, TE
core
Molecular Oncology, EarlyView.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source
Liver Catalase Activity of Patients with Gastric Cancer
, 1958 Kiyota Oh-Uti +4 more
openalex +2 more sources
FEBS Open Bio, EarlyView.The tumor microenvironment is a dynamic, multifaceted complex system of interdependent cellular, biochemical, and biophysical components. Three‐dimensional in vitro models of the tumor microenvironment enable a better understanding of these interactions and their impact on cancer progression and therapeutic resistance.
Salma T. Rafik +3 more
wiley +1 more source
Dec. 12. Cancer of Stomach, Liver, Spleen, and Mesenteric Glands [PDF]
EDW. RHOADS
openalex +1 more source